|
Almeida Capital is pleased to be a premier sponsor of AltAssets
|
FREE newsletter RSS
INTELLIGENCE
RECRUITMENT
KNOWLEDGE BANK
EVENTS
SECTOR ANALYSIS
HEDGE FUNDS
|
Click here for printer friendly page
Aescap on target to reach €150m hard cap later this year12/06/2007. Source: AltAssets. 
 New European biomedical venture capital fund Aescap Venture Management has announced that it has raised €102m for its maiden fund. The fund held a first closing on €59m in August 2006. The Amsterdam-headquartered firm expects to close the fund on its hard cap of €150m later this year.
Since its first closing, Aescap has invested in three biomedical companies: Affectis, ActoGeniX and ProtAffin. The firm aims to build a portfolio of 12 to 15 companies.
Aescap was founded by Michiel de Haan, founder and former CEO of Atlas Venture and Dr Dinko Valerio, founder and former CEO of Crucell, a Euronext/NASDAQ-listed biotechnology company.
Other partners are Patrick Krol, an entrepreneur and expert in life science marketing and business development, and Kreske Nickelsen, a previous director at 3i.
Copyright © 2007 AltAssets
|
 
|
|
|
